ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.
As a partner for clinical development, ICON will provide Shire with a full range of services including site and country feasibility, ethics, and regulatory submissions, clinical trial monitoring, project management, site, and study team support, medical management, and medical data review. Shire will also utilise ICON Central Laboratories’ extensive test menu from its global network of laboratories.
“We are proud that Shire Specialty Pharmaceuticals has selected ICON as a global partner and it is another endorsement of ICON’s expertise in operating under strategic partnership models,” commented Ciaran Murray, CEO, ICON plc. “ICON’s success is based on the right blend of development services and global testing facilities.. We look forward to building on our successful relationship with Shire to help them realize efficiencies as they seek to bring new products to market.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.